Chemotherapy for non‐small cell lung cancer
84 results
1 - 84
Chemotherapy for non‐small cell lung cancer- Second‐line chemotherapy for non‐small cell lung cancer
- Chemotherapy and surgery versus surgery alone in non‐small cell lung cancer
- Platinum versus non‐platinum chemotherapy regimens for small cell lung cancer
- Chemotherapy for advanced non‐small cell lung cancer in the elderly population
- Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer: Cochrane systematic review
- Adjuvant chemotherapy for resected early-stage non-small cell lung cancer: Cochrane systematic review
- Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer: Cochrane systematic review
- Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease: Cochrane systematic review
- Immune checkpoint inhibitors plus platinum‐based chemotherapy compared to platinum‐based chemotherapy with or without bevacizumab for first‐line treatment of older people with advanced non‐small cell lung cancer
- Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer
- Gefitinib for advanced non-small cell lung cancer: Cochrane systematic review
- First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell lung cancer
- Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer
- Therapeutic vaccines for advanced non‐small cell lung cancer
- Early versus late chest radiotherapy in patients with limited‐stage small cell lung cancer
- Best first‐line therapy for people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
- Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
- Surgery for local and locally advanced non‐small cell lung cancer
- Concurrent chemoradiotherapy in non‐small cell lung cancer
- Palliative radiotherapy regimens for patients with thoracic symptoms from non‐small cell lung cancer
- Palliative endobronchial brachytherapy for non‐small cell lung cancer
- Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non‐small‐cell lung cancer and EGFR mutation
- Anti‐TIGIT inhibitors plus PD‐1 or PD‐L1 inhibitors versus PD‐1 or PD‐L1 inhibitors for first‐line treatment of advanced non‐small cell lung cancer
- Surgery for limited‐stage small‐cell lung cancer
- PET‐CT for assessing mediastinal lymph node involvement in patients with suspected resectable non‐small cell lung cancer
- Postoperative radiotherapy for non‐small cell lung cancer
- Chemotherapy versus best supportive care for extensive small cell lung cancer: Cochrane systematic review
- Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases
- Erythropoietin or Darbepoetin for patients with cancer ‐ meta‐analysis based on individual patient data
- Exercise training undertaken by people within 12 months of lung resection for non‐small cell lung cancer
- Platinum‐containing regimens for triple‐negative metastatic breast cancer
- Platinum‐containing regimens for metastatic breast cancer
- Immunotherapy for advanced renal cell cancer: Cochrane systematic review
- Epidermal growth factor receptor blockers for the treatment of ovarian cancer
- Cannabis‐based medicines and medical cannabis for adults with cancer pain
- Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy
- Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer)
- Chemotherapy for advanced gastric cancer
- Anti‐epidermal growth factor receptor therapy for glioblastoma in adults